[2] Common side effects of enasidenib include nausea, vomiting, diarrhea, increased levels of bilirubin (substance found in bile), and decreased appetite.

[5] Enasidenib is indicated for the treatment of relapsed or refractory acute myeloid leukemia in adults with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test.

[2][3] Common side effects of enasidenib include nausea, vomiting, diarrhea, increased levels of bilirubin (substance found in bile) and decreased appetite.

[4][6] The efficacy of enasidenib was studied in a single-arm trial of 199 participants with relapsed or refractory acute myeloid leukemia who had isocitrate dehydrogenase-2 mutations as detected by the RealTime IDH2 Assay.

[4] Enasidenib was approved by the FDA in August 2017, for relapsed or refractory acute myeloid leukemia (AML) in people with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test.